Clinical Trials on Multiple Myeloma, Plasma Cell Leukemia in United Kingdom

Total 5984 results

Sanofi

Terminated

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Plasma Cell Myeloma

Taiwan, United States, Czechia, France, Greece, Spain
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Plasma Cell Myeloma

United States
Thomas Jefferson University

Completed

Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Notable Labs

Completed

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy ((ANSWer))

Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm

Spain, United States, Greece
Sanofi

Completed

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)

Plasma Cell Myeloma

France, Spain, Greece, Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Japan, New Zealand, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden, Taiwan, Turkey, United...
Massachusetts General Hospital
Pfizer

Recruiting

Elranatamab in R/R Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Carl Ola Landgren, MD, PhD
Bristol-Myers Squibb

Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Sunesis Pharmaceuticals

Completed

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-lymphoid Malignancies

United States
West Virginia University

Completed

Unrelated Umbilical Cord Blood (UBC)Transplantation

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Chronic Lymphocytic Leukemia (CLL) | Severe Aplastic Anemia | Acute Myelogenous Leukemia (AML) | Acute Lymphocytic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML)

United States
Wake Forest University Health Sciences

Completed

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Gilead Sciences

Completed

Phase I/II Study of hLL1 in Multiple Myeloma

Multiple Myeloma | Myeloma, Plasma-Cell | PLASMACYTOMA

United States
Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
Carevive Systems, Inc.

Recruiting

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Acute Myelogenous Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms | Multiple Myeloma and Malignant Plasma Cell Neoplasms

United States
Ohio State University Comprehensive Cancer Center

Completed

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Dartmouth-Hitchcock Medical Center

Completed

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (FluBuATG)

Myelodysplastic Syndromes | Leukemia, Myeloid | Multiple Myeloma | Lymphoma, Malignant | Myelofibrosis | Waldenstrom Macroglobulinemia | Leukemia, Lymphoid

United States
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Guy's and St Thomas' NHS Foundation Trust
King's College London

Recruiting

Real World Outcomes Using Novel Agents for AML in the UK

Acute Myeloid Leukemia

United Kingdom
King's College Hospital NHS Trust

Terminated

Pilot Study of Unrelated Cord Blood Transplantation

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Hodgkin Disease | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute

United Kingdom
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Royal Marsden NHS Foundation Trust
TC Biopharm

Unknown

Gamma Delta T Cells in AML

Acute Myeloid Leukemia

United Kingdom
Mayo Clinic

Completed

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Ajai Chari
Amgen

Completed

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
University Hospital Southampton NHS Foundation...
Royal Free and University College Medical School

Completed

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

Lymphoma | Myeloma | Acute Leukaemia | Chronic Leukaemia

United Kingdom
King's College Hospital NHS Trust

Completed

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma (CRD)

Multiple Myeloma

United Kingdom
Erimos Pharmaceuticals

Terminated

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Acute Lymphocytic Leukemia (ALL) | Leukemias | Adult T Cell Leukemia (ATL) | Chronic Myeloid Leukemia (CML-BP)

United States
Michael A. Thompson, MD, PhD
Vince Lombardi Cancer Clinic

Completed

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

Multiple Myeloma | Myeloma, Multiple | Myeloma-Multiple

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan

Mucositis | Multiple Myeloma and Plasma Cell Neoplasm

United States
Gilead Sciences

Terminated

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States, Czech Republic, Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Srinivas Devarakonda

Terminated

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Ohio State University Comprehensive Cancer Center
Celgene

Completed

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Bryostatin and Vincristine in B-Cell Malignancies

Stage III Multiple Myeloma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
Jason Valent

Completed

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

Multiple Myeloma | Kahler Disease | Myelomatosis | Plasma-Cell Myeloma

United States
Washington University School of Medicine

Completed

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (GVHD)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Multiple Myeloma | Leukemia, Myelogenous, Chronic

United States
Texas Oncology Cancer Center

Terminated

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Multiple Myeloma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States

Clinical Trials on Multiple Myeloma, Plasma Cell Leukemia in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations